The End Game
PAMA Isn't Fixed: The 2027 Cliff Lab Leaders Can't Ignore
PAMA is not "fixed," and the next real hit to lab reimbursement is closer than most executives think. Melissa Butterworth breaks down why the 2027 cliff is still ahead, why another easy congressional rescue may be less likely than before, and what lab leaders need to do right now to protect revenue.The headline everyone heard was "delay." The more important story is what Congress actually pushed back, what remains scheduled for 2027, 2028, and 2029, and why the reporting window opening in 2026 matters far more than a temporary patch. Melissa explains the latest legislative changes, the shifting CBO scoring problem that makes another one-year delay harder to pass, and why the industry conversation has moved from "Will we get another rescue?" to "What happens if we don't?"You'll discover: What PAMA really is and how prior rounds of cuts removed billions from the lab industry Why the 2026 reporting window directly impacts 2027 Medicare rates How the pending cuts could reach up to 15% on more than 800 laboratory procedures What the Results Act would change if it becomes law Why modeling revenue exposure now is no longer optional for outreach labs, hospital labs, and clinical labs Melissa also walks through the practical stakes for advisors and lab executives, including how to prepare clients for the possibility that the safety net Congress has relied on seven times may not appear again. If you are responsible for lab revenue, reimbursement strategy, or client advisory conversations, this episode gives you the urgency and the framework to act before the next deadline hits. Melissa Butterworth is the host of Endgame Insiders on Your Side and a senior voice in the medical lab industry. She brings a clear-eyed, advisory perspective to one of the most urgent reimbursement issues facing labs today.Perfect for lab executives, outreach leaders, consultants, and anyone who needs to understand what PAMA really means for 2027 and beyond.
